BioSpace News Archive

Technavio has announced its latest market research report titled global cryogenic equipment market 2019-2023.

Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that its transfemoral trans-septal (“TF/TS”) Tiara™ (“Tiara”) System was featured today in a tutorial session at the PCR London Valves 2019 meeting, which is taking place November 17-19 in London.

Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its abstract for the Phase III study of oral paclitaxel and encequidar (Oral Paclitaxel) in metastatic breast cancer has been selected for the press program of the 2019 San Antonio Breast Cancer Symposium (SABCS).

D-Cure is an organization whose mission is to advance diabetes research in Israel and to translate discoveries into state-of-the-art patient care for people with diabetes and related disorders.

Study results demonstrate IsletRx cells ability to balance blood sugar levels and maintain normal levels over time

Faraday Pharmaceuticals, a biopharmaceutical company focused on the development of small molecules for critical care medicine, today announced top-line results from its Phase 2 trial of FDY-5301 for the treatment of reperfusion injury following ST elevation myocardial infarction (STEMI)

Objective response rate, progression-free survival, duration of response and safety data from DS-8201 pivotal study in HER2 positive metastatic breast cancer (DESTINY-Breast01) to be unveiled

Dr. Ioannis Skaribas, a leader in the field of interventional pain management, is proud to announce that he was recently named a Fellow of the American Society of Anesthesiologists

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today it has been granted patents in Canada, South Korea, and Israel for its patent titled, “A3 adenosine receptor ligands for use in treatment of a sexual dysfunction” for its drug candidate CF602.

Diverse Biotech, Inc. www.diversebiotech.com, has announced it has opened its Headquarters at the Pennsylvania Biotechnology Center which is a prominent incubator for small growing life sciences companies in Doylestown, PA.